Взаимодействие с другими препаратами
Наиболее важные лекарственные взаимодействия представлены в таблице 3.11.
Таблица 3.11. Взаимодействие ингибиторов моноаминооксидазы с другими препаратамиa
Препарат | Эффекты |
Симпатомиметики (амфетамины, дофамин, эфедрин, адреналин, изопротеренол (Изупрел), метараминол, метилфенидат, оксиметазолин (Африн), норадреналин, фенилэфрин (Нео-синефрин), фенилпропаноламин, псевдоэфедрин (Судафед)) | Гипертонический криз |
Меперидин (Демерол и др.) | Лихорадка, делирий, гипертензия, гипотензия, повышение нервно-мышечной возбудимости, смерть |
Пероральные антидиабетические средства | Дополнительное снижение сывороточной глюкозы |
L-допа | Гипертонический криз |
Трициклические антидепрессантыb, венлафаксинc | Лихорадка, судорожные припадки, делирий |
СИОЗС, кломипрамин, триптофан | Тошнота, спутанность сознания, тревога, озноб, гипертермия, мышечная ригидность, потливость, гиперрефлексия, тахикардия, гипотензия, кома, смерть |
Бупропион | Гипертонический криз |
a — Это взаимодействие может происходить при использовании селегилина даже в низких дозах.
b — Трициклические антидепрессанты и ИМАО иногда применяются совместно.
с — Схожий эффект.
Литература.
Механизм действия.
Hyman SE, Nestler EJ. The molecular foundations of psychiatry. Washington, DC: American Psychiatric Association, 1993.
Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996; 153:15.
Показания.
Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. Arch Gen Psychiatry 1992; 49:139.
Goldbloom DS, Olmstead MR. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am J Psychiatry 1993; 150:770.
Golden RN, Rudarfer MV, Sherer MA, et al. Bupropion in depression: I. Biochemical effects and clinical response. Arch Gen Psychiatry 1988; 45:139.
Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995; 52:53.
Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993; 150:1169.
Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind placebo controlled crossover study. Am J Psychiatry 1995; 152:1368.
Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250.
Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomized, double-blind placebo-controlled study. Br J Psychiatry 1995; 167:374.
Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145:306.
Robinson RG, Kubos KL, Starr LB, et al. Mood disorders in stroke patients. Brain 1984; 107:81.
Robinson RG, Parikh RM, Lipsey JR, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993; 150:286.
Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151:1735.
Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55:391.
Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorders. J Clin Psychopharmacol 1995; 15:23.
Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430.
Steiner M. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332:1529.
Swedo SE, Leonard HL, Rapoport JL, et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 1989; 321:497.
Walsh ВТ, Stewart JW, Roose SP, et al. Treatment of bulimia with phenelzine. Arch Gen Psychiatry 1984; 41:1105.
Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline. JAMA 1997; 278:983.
Zisook S, Braff DL, Click MA. Monoamine oxidase inhibitors in the treatment of atypical depression. J Clin Psychopharmacol 1985; 5:31.
Применение.
Fontaine R, Ontiveros H, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55:234.
Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387.
Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49:769.
Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants. Arch Gen Psychiatry 1984; 41:782.
Quitkin FM, Stewart JW, McGrath PJ, et al. Loss of drug effects during continuation therapy. Am J Psychiatry 1993; 150:562.
Renaud J, Axelson D, Birmaher B. A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents. Drug Safety 1999; 20:59.
Task Force on the Use of Laboratory Tests in Psychiatry, American Psychiatric Association. Tricyclic antidepressants: blood level measurements and clinical outcome. Am J Psychiatry 1985; 142:155.
Побочные эффекты.
Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988; 8:323.
Gitlin MJ. Psychotropic medications and their effects on sexual dysfunction: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55:406.
Johnston AJ, Lineberry CG, Ascher JA. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52:450.
Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J 1982; 163:401.
Nelson JC, Jatlow PI, Brock J, et al. Major adverse reactions during desipramine treatment. Arch Gen Psychiatry 1982; 39:1055.
Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151:1069.
Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors. Part I: A comparative study. J Clin Psychopharmacol 1984; 4:270.
Rabkin J, Quitkin F, McGrath P, et al. Adverse reactions to monoamine oxidase inhibitors. Part I: Treatment correlates and clinical management. J Clin Psychopharmacol 1985; 5:2.
Rosenstein DL, Nelson C, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54:289.
Shulman KI, Walter SE, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989; 9:397.
Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705.
Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993; 54:459.
Передозировка.
Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59(suppl 15):45.
Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313:474.
Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984; 13:1137.